Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Low-dose Cyclophosphamide and Outpatient IL-2 in Metastatic Melanoma
NCT01833767Phase 2Withdrawn
- Sponsor
- Western Regional Medical Center
- Start
- Oct 2012
- Primary completion
- Dec 2015
- Modality
- Cytokines & Interferons, Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of cyclophosphamide, aldesleukin in melanoma, sponsored by Western Regional Medical Center. Planned start Oct 2012; status: withdrawn.
02
Drugs
cyclophosphamidealdesleukin
03
Conditions
melanoma
Beyond the preview
Go deeper on NCT01833767.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01833767.